Full genetic architecture of RAS cancer gene mutations in human tumors uncovered

Pre- and post-surgery immunotherapy combination shows promise for mesothelioma, Johns Hopkins-led study shows

A novel treatment approach using combination immunotherapy before and after surgery shows promise for patients with operable mesothelioma, according to a new study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg Kimmel Institute for Cancer Immunotherapy.

September 12, 2025

Vol.51 No.33

Clinical Roundup

Cyclin A/B RxL inhibitors restore G1–S-checkpoint in treatment of small cell lung cancer, DFCI research shows

A new class of drug results in cancer cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint known as the G1/S checkpoint, according to research gathered by the Oser Lab at Dana-Farber Cancer Institute.

September 12, 2025

Vol.51 No.33

In Brief

Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program

Antonio WolffMikala EgebladAntonio C. Wolff and Mikala Egeblad were named co-directors of the Breast and Gynecologic Cancer Program at Johns Hopkins Kimmel Cancer Center.

August 08, 2025

Vol.51 No.31

Clinical Roundup

“Power surges” on cancer cell membranes may fuel progression of disease, Johns Hopkins study finds

In a bid to better understand how cancer cells power their explosive growth and spread, scientists at Johns Hopkins Medicine have shed new light on the location and function of power-generating waves on cancer cell membranes. The scientists say the waves, generated by rhythmic propagation of enzymes that produce energy from glucose, could potentially be used to better stage cancers and as targets for new cancer drugs.

July 11, 2025

Vol.51 No.27

In Brief

Nicholas Jaidar named senior administrator for oncology at Johns Hopkins

Nicholas M. Jaidar was named senior administrator for oncology at the Department of Oncology at the Johns Hopkins University School of Medicine and the Johns Hopkins Hospital.

June 27, 2025

Vol.51 No.25

Clinical Roundup

Targeting Pol 1 could rewire cancer cells and suppress tumor growth, Johns Hopkins study finds

Researchers at the Johns Hopkins Kimmel Cancer Center and Department of Radiation Oncology and Molecular Radiation Sciences uncovered a new tumor-suppressive response that could lead to novel therapies targeting hard-to-treat cancers.

June 20, 2025

Vol.51 No.24

Full genetic architecture of RAS cancer gene mutations in human tumors uncovered

YOU MAY BE INTERESTED IN

Pre- and post-surgery immunotherapy combination shows promise for mesothelioma, Johns Hopkins-led study shows

Cyclin A/B RxL inhibitors restore G1–S-checkpoint in treatment of small cell lung cancer, DFCI research shows

Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program

“Power surges” on cancer cell membranes may fuel progression of disease, Johns Hopkins study finds

Nicholas Jaidar named senior administrator for oncology at Johns Hopkins

Targeting Pol 1 could rewire cancer cells and suppress tumor growth, Johns Hopkins study finds

Renew today!

Subscriber content

Never miss an issue!

Login